monohydrochloride 1- ((2- adamantyl)amino)acetyl- 2- cyano- (S)- pyrrolidine

Also Known As:

1-((2-adamantyl)amino)acetyl-2-cyano-(S)-pyrrolidine, monohydrochloride; PKF-275-055; PKF275-055

Networked: 5 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Adamantane: 182
        monohydrochloride 1-((2-adamantyl)amino)acetyl-2-cyano-(S)-pyrrolidine: 5
    - Bridged-Ring Compounds: 1
      - Adamantane: 182
        monohydrochloride 1-((2-adamantyl)amino)acetyl-2-cyano-(S)-pyrrolidine: 5
- Nitriles: 227
  - monohydrochloride 1-((2-adamantyl)amino)acetyl-2-cyano-(S)-pyrrolidine: 5
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrrolidines: 115
    - monohydrochloride 1-((2-adamantyl)amino)acetyl-2-cyano-(S)-pyrrolidine: 5

Experts

1.	Akarte, Atul Sureshrao: 2 articles (09/2012 - 01/2012)
2.	Gandhi, Sonia: 2 articles (09/2012 - 01/2012)
3.	Srinivasan, B P: 2 articles (09/2012 - 01/2012)
4.	Hayami, Noriyuki: 1 article (05/2016)
5.	Iwasaki, Yu-Ki: 1 article (05/2016)
6.	Murakawa, Yuji: 1 article (05/2016)
7.	Sekiguchi, Akiko: 1 article (05/2016)
8.	Yamashita, Takeshi: 1 article (05/2016)
9.	Hirota, Daisho: 1 article (01/2014)
10.	Kajitani, Nobuo: 1 article (01/2014)

Related Diseases

1.	Diabetic Nephropathies (Diabetic Nephropathy) 01/17/2014 - "These results indicate that DPP-4 inhibitor, PKF275-055, have reno-protective effects through anti-inflammatory action in the early stage of diabetic nephropathy. " 01/17/2014 - "PKF275-055 decreased urinary albumin excretion and ameliorated histological change of diabetic nephropathy. "
2.	Type 2 Diabetes Mellitus (MODY) 09/29/2012 - "The present studies indicate that PKF-275-055 is a novel selective DPP-IV inhibitor having potential to reduce inflammation that might be a potential agent for type 2 diabetes." 01/15/2012 - "The present preclinical studies indicate that PKF-275-055 is a novel selective DPP-IV inhibitor with long-acting antidiabetic effect that might be a potential agent for type 2 diabetes." 01/15/2012 - "This study examined chronic (once-a-day dosing for 8 weeks) effects of the DPP-4 inhibitor PKF-275-055 (1, 3, and 10mg/kg) on β-cell regeneration and plasma DPP-IV activity, intact GLP-1, glucose, and insulin after an oral glucose load in neonatal wistar rats injected with streptozotocin (STZ) (n2-STZ model), a recognized model of type 2 diabetes. "
3.	Inflammation (Inflammations) 09/29/2012 - "Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats." 09/29/2012 - "The present studies indicate that PKF-275-055 is a novel selective DPP-IV inhibitor having potential to reduce inflammation that might be a potential agent for type 2 diabetes."
4.	Peripheral Nervous System Diseases (PNS Diseases) 01/01/2012 - "Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy."
5.	Hypoglycemia (Reactive Hypoglycemia) 01/15/2012 - "In contrast, PKF-275-055 (1-10mg/kg) did not cause hypoglycemia in fasted normal rats. "

Related Drugs and Biologics

1.	Dipeptidyl-Peptidase IV Inhibitors
2.	Streptozocin (Streptozotocin)
3.	Glucagon-Like Peptide 1 (GLP 1)
4.	Insulin (Novolin)
5.	Hypoglycemic Agents (Hypoglycemics)
6.	Glucose (Dextrose)
7.	Therapeutic Uses
8.	Glyburide (Glibenclamide)
9.	Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
10.	Blood Glucose (Blood Sugar)